NDASUBCUTANEOUSSOLUTION1 Generic Approved
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
6/8 — Strong
SAXENDA (liraglutide) by Novo Nordisk is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for glp-1 receptor agonist [epc]. First approved in 2014.
Drug data last refreshed 25m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SAXENDA (liraglutide) is a subcutaneous GLP-1 receptor agonist approved in 2014 for chronic weight management in adults with obesity or overweight with weight-related comorbidities. It works by mimicking glucagon-like peptide-1, a hormone that regulates appetite and blood sugar, thereby reducing caloric intake and promoting weight loss.
$0.034BPart D
PeakStable
11.0 years to LOEProduct is in peak lifecycle stage with stable but modest Part D utilization; commercial teams are focused on market maintenance and defending share against stronger GLP-1 competitors.
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
GLP-1 Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Started Nov 2025
75 enrolled
Obesity
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
Started Apr 2024
300 enrolled
Obesity
INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records
Started Sep 2022
0Obesity
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
Started Jul 2022
0Diabetes Mellitus, Type 2
Efficacy of Liraglutide Therapy in Patients With IPAA
Started Mar 2022
8 enrolled
PouchitisIrritable Pouch Syndrome
Worked on SAXENDA at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.